ClinicalTrials.gg
CompletedNCT01306175Updated Jun 17, 2014Results posted

Drug Interaction Study of Digoxin and BI 10773

A Phase 1 interventional study of Digoxin plus BI 10773 and Digoxin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-17.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The objective of the study is to investigate the relative bioavailability of digoxin after concomitant multiple oral administration of BI 10773 and a single dose of digoxin in comparison to digoxin given alone to healthy male and female subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Healthy male and female subjects

Exclusion criteria

Exclusion criteria:

-Any relevant deviation from healthy conditions

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Digoxin alone (Reference)

    Tablet, oral administration with 240 mL water

    Drug: Digoxin

  • Experimental
    Digoxin plus BI 10773 (Test)

    Tablets, oral administration with 240 mL water

    Drug: Digoxin plus BI 10773

Interventions

  • DrugDigoxin plus BI 10773

    Drug pages: Digoxin · Empagliflozin

    Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily

  • Digoxin 0.5 mg as single dose

06

What researchers measure

Primary outcomes

  1. Digoxin: Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to infinity.

    Time frame: 1.5 hours (h) prior to the first dose and 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 96h after the first dose

  2. Digoxin: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of digoxin, per period.

    Time frame: 1.5 hours (h) prior to the first dose and 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 96h after the first dose

Secondary outcomes

  1. Digoxin: Area Under the Curve 0 to Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to the time of the last quantifiable data point.

    Time frame: 1.5 hours (h) prior to the first dose and 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 96h after the first dose

07

Results

Posted Jun 17, 2014

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneStudy Total
Started20
Completed20
Not completed0
Washout Period of at Least 14 Days
Participant flow — Washout Period of at Least 14 Days
MilestoneStudy Total
Started20
Completed20
Not completed0
Second Intervention
Participant flow — Second Intervention
MilestoneStudy Total
Started20
Completed20
Not completed0

Outcome measures

PrimaryDigoxin: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to infinity.

Time frame:
1.5 hours (h) prior to the first dose and 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 96h after the first dose
Reported as:
Geometric mean · ng-h/mL
Digoxin: Area Under the Curve 0 to Infinity (AUC0-∞)
ng-h/mLDigoxin AloneDigoxin and Empa
Digoxin: Area Under the Curve 0 to Infinity (AUC0-∞)37.8 ± 23.239.9 ± 26.0
PrimaryDigoxin: Maximum Measured Concentration (Cmax)

Maximum measured concentration of digoxin, per period.

Time frame:
1.5 hours (h) prior to the first dose and 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 96h after the first dose
Reported as:
Geometric mean · ng/mL
Digoxin: Maximum Measured Concentration (Cmax)
ng/mLDigoxin AloneDigoxin and Empa
Digoxin: Maximum Measured Concentration (Cmax)1.97 ± 43.32.25 ± 33.8
SecondaryDigoxin: Area Under the Curve 0 to Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to the time of the last quantifiable data point.

Time frame:
1.5 hours (h) prior to the first dose and 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 96h after the first dose
Reported as:
Geometric mean · ng*h/mL
Digoxin: Area Under the Curve 0 to Last Quantifiable Data Point (AUC0-tz)
ng*h/mLDigoxin AloneDigoxin and Empa
Digoxin: Area Under the Curve 0 to Last Quantifiable Data Point (AUC0-tz)24.8 ± 24.828.4 ± 24.3

Adverse events

Collected over First administration of trial medication until 7 days after last administration of trial medication for Digoxin and BI 10773 + Digoxin, 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Digoxin Alone—0/20 (0%)2/20 (10%)
Digoxin and Empa—0/20 (0%)0/20 (0%)
Most frequent other events
Most frequent other events
EventDigoxin AloneDigoxin and Empa
FatigueGeneral disorders2/200/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Study Total
Mean34.3 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Study Total
Female9
Male11
08

Study locations

1 site
  • 1245.40.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

References and documents

Publications

  • Macha S, Sennewald R, Rose P, Schoene K, Pinnetti S, Woerle HJ, Broedl UC. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013 Mar;35(3):226-35. doi: 10.1016/j.clinthera.2013.02.015. PubMed 23497760 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011 and a primary completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2011
First posted
Mar 1, 2011
Start
Feb 2011
Primary completionActual
Apr 2011
Results first posted
Jun 17, 2014
Last update
Jun 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01306175
Responsible party
Sponsor
First posted
Mar 1, 2011
Start date
Feb 2011
Primary completion
Apr 2011
Results posted
Jun 17, 2014
Last update
Jun 17, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Digoxin · Empagliflozin

Start the discussion